ADTX
AditxtยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ADTX Profile
Aditxt, Inc.
A biotech innovation company that develops technologies with a focus on monitoring and modulating the immune system
2569 Wyandotte Street, Suite 101, Mountain View, CA 94043
--
Aditxt, Inc., was incorporated under the laws of the State of Delaware on September 28, 2017. The company is a preclinical stage life sciences company dedicated to prolonging the lives of transplant patients and improving the quality of life of transplant patients. They have an exclusive global license for this nucleic acid-based technology called Apoptotic DNA Immunotherapy (ADi), which utilizes new methods to mimic their bodies' natural induction of tolerance to their own tissues. The company plans to develop ADi products for organ transplantation, skin grafting and wound healing, with an initial focus on skin grafts and other organ and tissue allografts.
